Compare Adaptive Biotechnologies Corp (ADPT) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Constellation Energy Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Constellation Energy Corporation trades at $244.65 (market cap $85.60B). The key difference: Constellation Energy Corporation is far larger — about 25.7× Adaptive Biotechnologies Corp's market cap, and Constellation Energy Corporation pays a 0.71% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CEG | |
|---|---|---|
Market Cap | $3.33B | $85.60B |
Sector | Health | Energy |
52-Week High | $22.37 | $403.95 |
52-Week Low | $10.24 | $236.50 |
Enterprise Value | $3.19B | $107.27B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CEG trades at $245.87, up 2.77% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in two of the last three quarters. The company benefits from rising AI-driven electricity demand and long-term nuclear power purchase agreements with major clients like Walmart and Meta. Cash flow from operations remains robust at $4.24 billion for 2025, supporting dividend payments and growth investments.
The stock presents a compelling opportunity with a consensus price target of $343.50, implying significant upside. However, risks include high capital expenditures in 2026 leading to negative net cash flow and competitive pressures in the utilities sector. Analyst sentiment is strongly bullish with 70% buy ratings, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
